An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of Delandistrogene Moxeparvovec Following Plasmapheresis in Subjects With Duchenne Muscular Dystrophy and Pre-existing Antibodies to AAVrh74

Study Summary

This is a gene transfer therapy study evaluating the safety of and delandistrogene moxeparvovec dystrophin protein expression from delandistrogene moxeparvovec following therapeutic plasma exchange (plasmapheresis) in ambulatory male participants with DMD and pre-existing antibodies to AAVrh74 over a period of 59 weeks.

Interventions

Study Locations

Facility	City	State	Country
University of Florida, College of Medicine	Gainesville	Florida	United States
Washington University School of Medicine in St. Louis	St Louis	Missouri	United States
Nationwide Children's Hospital	Columbus	Ohio	United States

Official Trial Information

View on ClinicalTrials.gov